S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$58.22
+1.43 (+2.52%)
(As of 06/2/2023 ET)
Compare
Today's Range
$56.34
$58.64
50-Day Range
$42.20
$58.50
52-Week Range
$37.82
$79.40
Volume
381,347 shs
Average Volume
544,354 shs
Market Capitalization
$3.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.84

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
25.1% Upside
$72.84 Price Target
Short Interest
Healthy
5.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Blueprint Medicines in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.55) to ($7.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

505th out of 983 stocks

Pharmaceutical Preparations Industry

242nd out of 486 stocks


BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Update
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Analyst Expectations for Blueprint Medicines's Future
Blueprint Medicines (BPMC) Gets a Buy from JMP Securities
See More Headlines

BPMC Price History

BPMC Company Calendar

Last Earnings
5/04/2023
Today
6/03/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$72.84
High Stock Price Forecast
$114.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+25.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$-557,520,000.00
Net Margins
-284.02%
Pretax Margin
-281.29%

Debt

Sales & Book Value

Annual Sales
$204.59 million
Book Value
$6.85 per share

Miscellaneous

Free Float
58,399,000
Market Cap
$3.52 billion
Optionable
Optionable
Beta
0.71

Social Links


Key Executives

  • Kathryn HavilandKathryn Haviland
    President, Chief Executive Officer & Director
  • Christina RossiChristina Rossi
    Chief Operating Officer
  • Michael Landsittel
    Chief Financial Officer
  • Christopher K. Murray
    Senior Vice President-Technical Operations
  • Janet Loesberg
    Senior Vice President-Global Medical Affairs













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 1 sell rating, 5 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

15 brokers have issued 1 year price objectives for Blueprint Medicines' stock. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they anticipate the company's share price to reach $72.84 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the start of the year. Since then, BPMC shares have increased by 32.9% and is now trading at $58.22.
View the best growth stocks for 2023 here
.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,580,000 shares, a decrease of 5.8% from the April 30th total of 3,800,000 shares. Based on an average daily trading volume, of 598,200 shares, the short-interest ratio is currently 6.0 days.
View Blueprint Medicines' Short Interest
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($2.15) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.51. The biotechnology company had revenue of $63.29 million for the quarter, compared to analysts' expectations of $41.85 million. Blueprint Medicines had a negative net margin of 284.02% and a negative trailing twelve-month return on equity of 100.31%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the company posted ($1.79) earnings per share.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.59%), BlackRock Inc. (10.95%), Wellington Management Group LLP (8.50%), Price T Rowe Associates Inc. MD (8.18%), State Street Corp (4.56%) and JPMorgan Chase & Co. (2.57%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $58.22.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.52 billion and generates $204.59 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -